Your browser doesn't support javascript.
loading
αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib.
Fang, Juemin; Ding, Na; Guo, Xinling; Sun, Yan; Zhang, Zhiwei; Xie, Bailu; Li, Zhong; Wang, Hui; Mao, Wei; Lin, Zhicai; Qin, Fei; Yuan, Min; Chu, Wenqi; Qin, Huanlong; Qian, Qijun; Xu, Qing.
Affiliation
  • Fang J; Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
  • Ding N; Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China.
  • Guo X; Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
  • Sun Y; Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
  • Zhang Z; Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
  • Xie B; Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China.
  • Li Z; Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
  • Wang H; Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
  • Mao W; Department of Oncology, Affiliated Hospital of Hebei University of Engineering, Handan 056002, China.
  • Lin Z; Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
  • Qin F; Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
  • Yuan M; Shanghai Cell Therapy Research Institute, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China.
  • Chu W; Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
  • Qin H; Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China.
  • Qian Q; Department of Medical Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China.
  • Xu Q; Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China.
J Immunother Cancer ; 9(2)2021 02.
Article in En | MEDLINE | ID: mdl-33589520
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Immunotherapy, Adoptive / Carcinoma, Ovarian Epithelial / Liver Neoplasms / Antibodies, Monoclonal / Neoplasm Recurrence, Local Limits: Female / Humans / Middle aged Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Immunotherapy, Adoptive / Carcinoma, Ovarian Epithelial / Liver Neoplasms / Antibodies, Monoclonal / Neoplasm Recurrence, Local Limits: Female / Humans / Middle aged Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: China